Elliott Publishes Statement on Ahold Delhaize
Elliott Advisors (UK) Limited, which advises funds (together “Elliott”), confirms that it is a significant investor in Ahold Delhaize N.V. (“Ahold Delhaize” or the “Company”) and that it holds an economic interest in excess of 3% of the Company.
Elliott’s investment in Ahold Delhaize reflects its strong conviction in the quality and prospects of the Company’s underlying assets, and in particular the strength and potential of bol.com. Elliott supports Ahold Delhaize’s decision to begin the process of separating bol.com, which should help unlock significant value for shareholders, thus far concealed within the Company’s structure. A more independent bol.com would be a stronger business with a more robust marketplace, benefitting consumers, vendors, and employees alike.
Elliott looks forward to continuing its constructive dialogue with Ahold Delhaize.
About Elliott
Elliott Investment Management L.P. manages approximately $48 billion of assets. Its flagship fund, Elliott Associates, L.P., was founded in 1977, making it one of the oldest funds under continuous management. The Elliott funds' investors include pension plans, sovereign wealth funds, endowments, foundations, funds-of-funds, high net worth individuals and families, and employees of the firm. Elliott Advisors (UK) Limited is an affiliate of Elliott Investment Management L.P.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211117005697/en/
Contact information
London
Sarah Rajani CFA
Elliott Advisors (UK) Limited
T: +44 (0)20 3009 1475
srajani@elliottadvisors.co.uk
Netherlands
David Brilleslijper / Alice Jentink
Comprehensive Strategies
M: +31 (0)6 109 425 14 / +31 (0)65188 7210
T: +31 (0)20 822 01 01
david@comprehensivestrategies.nl / alice@comprehensivestrategies.nl
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Loomis Sayles Proudly Celebrates 100 Years of Client Commitment and Investment Excellence6.1.2026 14:00:00 EET | Press release
Loomis, Sayles & Company, the investment manager with $425 billion in assets under managementi, proudly marks its centennial year, celebrating a legacy of independent thinking and a relentless commitment to helping clients achieve their goals. Founded in January 1926, Loomis Sayles has grown to serving over 1,000 institutional clients in 28 countries offering differentiated investment solutions across fixed income, equity and alternative markets. “Reaching a century is rare. Doing so with the continued trust of clients and partners around the world is exceptional and we are honored to celebrate with all of them,” said Kevin Charleston, Chairman and Chief Executive Officer of Loomis Sayles. “As Loomis Sayles celebrates its 100th anniversary, we look ahead with gratitude for the opportunity to continue growing and innovating alongside those we serve.” A Legacy of Client Commitment and High-Conviction Analysis Throughout its history, Loomis Sayles has remained steadfast in its mission: to
Compass Pathways Establishes Strategic Collaboration with Radial to Innovate Patient Experience and Inform Potential Delivery Model of COMP3606.1.2026 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into its seventh strategic collaboration, with Radial Health, Inc., a growing national network of interventional psychiatry practices leveraging technology and operations expertise to optimize models of care delivery. This collaboration will further help to inform the development of scalable delivery models for investigational COMP360 psilocybin treatment, if FDA approved. The agreement with Radial expands the set of collaborations that Compass has established representing a broad spectrum of settings where people living with mental health conditions receive their care in the United States. Radial is building a national network of clinics across the U.S., delivering interventional, evidence-based treatments for mental health conditions. The co-founders have a mission-driven background in designing customer-centric care and bui
Hitachi Launches Expanded HMAX Solutions Accelerating Social Innovation Globally Across Industries6.1.2026 12:30:00 EET | Press release
Hitachi, Ltd. (TSE:6501, "Hitachi") today introduced HMAX by Hitachi at CES 2026. HMAX by Hitachi is a suite of next-generation solutions that brings the power of AI to social infrastructure. By harnessing vast data from physical and digital assets, integrating advanced AI, and applying Hitachi’s unmatched domain expertise, HMAX tackles the most complex social infrastructure challenges—maximizing outcomes and value for our clients and society. These solutions are derived from the formalized HMAX design principles, integrating a dynamic collection of advanced technologies and a robust partner ecosystem that helps elevate end-system reliability and performance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106885363/en/ HMAX by Hitachi: the suite of next-generation solutions that brings the power of AI to social infrastructure. HMAX combines data collected from physical and digital assets such as sensors, industrial equipm
Pandorum Technologies and Nucelion Therapeutics Announce Strategic Collaboration to Manufacture Exosome-Based Tissue Regenerative Therapy for Ocular Diseases in APAC Markets6.1.2026 12:00:00 EET | Press release
Pandorum Technologies, a clinical-stage regenerative medicine company building a next-generation platform for programmable tissue regeneration, today announced a strategic collaboration with Hyderabad based Nucelion Therapeutics, a specialized contract research, development and manufacturing organization (CRDMO), to expand manufacturing capabilities for Pandorum’s exosome-based therapeutic platform across the Asia-Pacific (APAC) region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106214233/en/ This strategic collaboration aligns with a shared vision, as Pandorum’s asset(s) progress toward clinical trials. By leveraging Nucelion Therapeutics’ manufacturing capabilities, the partnership supports regional supply and regulatory readiness, marking a strategic step forward. Furthermore, it reaffirms India’s growing capability to develop and manufacture cutting-edge biologic therapies for the world. “Pandorum is building a gl
KAYTUS Completes 100-Cabinet Liquid-Cooled Data Center in Europe in Four Months6.1.2026 10:02:00 EET | Press release
KAYTUS announced that it has accelerated the deployment of large-scale liquid-cooled AI data centers through its integrated turnkey service. By combining deployment and commissioning, KAYTUS delivers a one-stop, end-to-end service, from installation to optimization and launch. Recently, KAYTUS completed the delivery of a 100-cabinet, high-density liquid-cooled AI data center in Europe in just four months, up to 80% faster than traditional deployment models. Through professional performance testing and tuning, overall system performance was improved by 20%, enabling a stable, high-efficiency business launch through on-site optimization and customization. This accelerated and resilient delivery addresses urgent AI infrastructure timelines and provides a scalable blueprint for deploying high-density liquid-cooled clusters across Europe. The customer is a European infrastructure unicorn delivering compute, storage, and networking services to the e-commerce, fintech, and digital media secto
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom